Chronic rapamycin lowers the apoptotic threshold in mTOR-hyperactivated senescent kidney tubular cells while simultan...
IF intermittent high-dose oral fisetin (100 mg/kg by gavage on days 1–2 and 15–16 of each four-week cycle) is co-administered with chronic encapsulated rapamycin (14 ppm in chow, equivalent to ~2.24 mg/kg/day) to 22–24-month-old male and female C57BL/6J mice for 8 weeks, targeting aged kidney tubular epithelium,
THEN kidney senescent cell burden will be reduced by ≥40% beyond either monotherapy (measured by p16^INK4a^+ tubular cell density via immunofluorescence, SA-β-galactosidase activity in kidney cortex sections, and SASP cytokine levels IL-6 and MMP-3 in kidney homogenates), accompanied by improved glomerular filtration rate proxy (urinary albumin-to-creatinine ratio reduction), and reduced kidney fibrosis (collagen deposition by Sirius Red),
BECAUSE the following sequential mechanistic chain links rapamycin-mediated mTOR suppression and autophagy induction to fisetin-mediated BCL-2/BCL-xL apoptotic priming in a convergent two-hit clearance model:
-
Aged kidney proximal tubular cells accumulate high senescent cell burden; these cells engage the PI3K/AKT/mTOR survival axis to resist apoptotic clearance, a pathway also responsible for transcriptional upregulation of BCL-2 and BCL-xL anti-apoptotic proteins — chronic rapamycin suppresses mTOR complex 1 (mTORC1), reducing AKT-driven transcription of BCL-2 family survival genes and thereby lowering the apoptotic threshold specifically in mTOR-hyperactivated senescent tubular cells [SPECULATIVE link between mTOR suppression and BCL-2 transcriptional downregulation, supported by known PI3K/AKT/mTOR → BCL-2 axis crosstalk, no direct kidney senescence DOI available in Evidence Set].
-
Fisetin, established as the most potent senotherapeutic flavonoid among ten tested — reducing senescence markers across multiple tissues in progeroid and aged mice including kidneys — exerts senolytic action via BCL-2 and BCL-xL inhibition and PI3K/AKT pathway suppression, selectively inducing apoptosis in senescent cells primed by step 1 above (Fisetin is a senotherapeutic that extends healthspan and lifespan)[https://doi.org/10.1016/j.ebiom.2018.09.015].
-
BCL-xL inhibition is the dominant mechanism for senescent cell killing: selective BCL-xL blockade (as with A-1155463) significantly reduces viability of senescent cells, whereas BCL-2-selective inhibition has comparatively weaker effects — meaning fisetin's dual BCL-2/BCL-xL activity delivers broader apoptotic coverage across senescent tubular cell subpopulations than either target alone (Clearance of therapy-induced senescent tumor cells by ABT-263)[https://doi.org/10.1002/1878-0261.12761].
-
Critically, fisetin's effects on senescence markers persist well beyond the molecule's rapid terminal half-life in circulation, indicating that brief pharmacological engagement triggers durable downstream apoptotic cascades — this supports the use of intermittent high-dose regimens where fisetin is not continuously present, compatible with concurrent chronic rapamyci...
SENS category: RepleniSENS
Key references: • doi.org/10.1016/j.ebiom.2018.09.015]. • doi.org/10.1002/1878-0261.12761]. • doi.org/10.1038/s41586-020-2403-9]. • doi.org/10.1126/science.abe4832]. • doi.org/10.3389/fphar.2020.553690].